Clinical trials: High Risk Medications
HIV-1 Infection
A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma
The purpose of this study is to evaluate the safety and the feasibility, and the success of engraftment of the introduction of Cal-1 gene-transduced haematopoietic cell populations (Ttn and HSPCtn) in patients with HIV-1-related…
- Trial name
- GENHIV (NCT03593187)
- Testing
- Cal-1 (LVsh5/C46) drug product
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder
Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
The purpose of this study was to evaluate the feasibility and compliance with a novel method for assessing mood and cognition in participants with major depressive disorder (MDD).
- Trial name
- NCT03067506
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Takeda
Obesity & Overweight
Motivational Interviews Based on the Five-Step (5A) Model on Obesity Risk
The goal of this clinical trial is to learn if a structured motivational interviewing program based on the Five-Step (5A) model works to promote healthy lifestyle behaviors in individuals at high risk of obesity.
- Trial name
- NCT07769736
- Testing
- Motivational Interviewing
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istinye University
Ischemic Stroke, High Blood Pressure
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
ENCHANTED is an independent, investigator initiated, international collaborative, quasi-factorial randomised controlled trial involving a package of 2 linked comparative randomised treatment arms, which aims to address 4 key…
- Trial name
- ENCHANTED (NCT01422616)
- Testing
- Low-dose rtPA, Standard-dose rtPA, Intensive blood pressure (BP) lowering
- Where
- Australia
- Volunteers
- 4,587 people
- Sponsor
- The George Institute
Bladder Cancer
Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer
Disease recurrence and progression is a major issue in high risk non-muscle-invasive bladder cancer (NMIBC). The current study compares two adjuvant instillation therapies in the treatment of high risk NMIBC.
- Trial name
- FB10 (NCT03664869)
- Testing
- BCG instillation therapy, Sequential BCG and EMDA mitomycin C
- Where
- 7 sites in Finland
- Volunteers
- 300 people
- Sponsor
- Turku University Hospital
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine.
- Conditions
- Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- PANTHER (NCT03268954)
- Testing
- Azacitidine, Pevonedistat
- Where
- 242 sites in United States, Australia and 18 more
- Volunteers
- 454 people
- Sponsor
- Takeda
Chronic Kidney Disease, Pneumonia
Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients
Chronic kidney disease is a severe medical problem in Taiwan public health issue, which the highest incidence and prevalence rate in the world.Proton pump inhibitors may increase the risk of pneumonia appearance, which were…
- Trial name
- NCT01588886
- Volunteers
- 9,000 people
- Sponsor
- Far Eastern Memorial Hospital
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00006012
- Testing
- filgrastim, amifostine trihydrate, cisplatin
- Where
- 84 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostatic Intraepithelial Neoplasia
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study.
- Trial name
- NCT00028353
- Testing
- GTX-006 (Acapodene)
- Where
- 25 sites in United States
- Volunteers
- 500 people
- Sponsor
- GTx
Sickle Cell Trait, Sickle Cell Disease
Blood Sampling for Research Related to Sickle Cell Disease
This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease.
- Conditions
- Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
- Trial name
- NCT00542230
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypertension, Coronary Disease
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications.
- Conditions
- Hypertension, Coronary Disease, Cerebrovascular Accident
- Trial name
- NCT00563901
- Where
- 2 sites in United States
- Volunteers
- 37,939 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Tuberculosis
High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)
Isoniazid (INH) is a drug commonly used to treat tuberculosis (TB) worldwide. Sometimes, the bacteria that cause TB can become resistant to INH.
- Trial name
- NCT01936831
- Testing
- Isoniazid, Vitamin B6
- Where
- 2 sites in Haiti, South Africa
- Volunteers
- 282 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hypertension, High Blood Pressure
N-of-1 Trials for Blood Pressure Medications in Adults
Many patients want to know which blood pressure medication is the best for them. In this study, we will test the feasibility of a new approach to determining the best blood pressure medication for individual patients by…
- Trial name
- NCT02744456
- Testing
- Losartan, Amlodipine, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Education, Nursing
The Effectiveness of a Chatbot-facilitated High Alert Medication Education for 2-year Post Graduate Nurses
This study involves three stages. In the first stage, qualitative research design is used to understand clinical nurses' learning needs on high alert medication.
- Trial name
- NCT05985005
- Testing
- online simulation of high alert medication safety training
- Where
- Taiwan
- Volunteers
- 124 people
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
Glioblastoma Multiforme
Cancer Stem Cell High-Throughput Drug Screening Study
A study to determine the safety of CSC/ HTS-based combination drug therapy in subjects who have GBM that has recurred or progressed following prior radiation therapy and TMZ.
- Trial name
- NCT02654964
- Testing
- Combination Drug Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Swedish Medical Center
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00004264
- Testing
- amifostine trihydrate, cisplatin, docetaxel
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Leiomyosarcoma
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with leiomyosarcoma.
- Trial name
- TTI-621-03 (NCT04996004)
- Testing
- Ontorpacept (TTI-621), Doxorubicin
- Where
- 23 sites in United States
- Volunteers
- 76 people
- Sponsor
- Pfizer
Substance Use Disorders
Exercise Training as Medicine for Substance Use Disorder Patients
This study compares the effects of high dose and low dose, high intensity, endurance training and strength training in substance use disorder patients.
- Trial name
- NCT04065334
- Testing
- High dose training, low dose training
- Where
- Norway
- Volunteers
- 171 people
- Sponsor
- St. Olavs Hospital
Soft Tissue Sarcoma, Child
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors
This is a prospective, open-label, single-arm, single-center study designed to evaluate the feasibility of using patient-derived organoid drug sensitivity analysis to guide chemotherapy for pediatric patients with refractory and…
- Trial name
- NCT07528079
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine